According to CONCORD-3, the largest global study of cancer survival ever conducted, Korea's 5-year stomach cancer survival rate is 69% — among the highest in the world. For colon cancer, it's 72%. These numbers come from peer-reviewed data. They deserve to be part of your decision.
A cancer diagnosis is, among other things, a crash course in information asymmetry. Suddenly you're trying to evaluate hospitals, surgeons, treatment protocols, and survival statistics — often within days, in a state of shock, with well-meaning people telling you that you should just trust your doctor. Your local doctor. At your local system.
What most people don't know — what most oncologists don't bring up, because it's outside their lane — is that survival outcomes for certain cancers vary significantly by country. And for several of the most common cancers globally, South Korea ranks among the best in the world.
This isn't conjecture. It's published science.
CONCORD-3 is not a press release. It's a peer-reviewed analysis published in The Lancet in 2018, covering 37.5 million cancer patients across 71 countries — the largest coordinated cancer survival study ever conducted. It was designed specifically to compare outcomes across healthcare systems in a rigorous, standardized way.
The findings on South Korea are striking. For stomach cancer — one of the most challenging gastrointestinal malignancies — Korea's 5-year survival rate was 69%, placing it among the highest in the world. For comparison, global survival rates for this cancer in most countries fall below 30%. Korea also recorded high survival rates for colorectal cancer: 72% for colon cancer and 71% for rectal cancer.
Source: Allemani C et al., "Global surveillance of trends in cancer survival 2000–14 (CONCORD-3)," The Lancet, 2018. PMC5879496.
"Korea, Denmark, the Netherlands, and Norway saw survival increases greater than 10 percent over the 15-year CONCORD-3 analysis period — among the highest improvements of any country studied."
The answer isn't mysterious. It's systematic.
Korea runs one of the most effective national cancer screening programs in the world. For stomach cancer specifically, regular endoscopic screening has transformed who gets diagnosed — and when. In 2001, 39% of stomach cancers in Korea were caught at an early stage. By 2016, that number was 73%. Earlier diagnosis means more treatment options, better surgical candidates, and dramatically better survival odds.
Source: Korean National Cancer Screening Program (NCSP), Journal of Preventive Medicine and Public Health, 2023.
In oncological surgery, volume matters. A surgeon who has performed 2,000 gastrectomies has better outcomes than one who has performed 200 — full stop. Korea's major cancer hospitals handle volumes that few Western centers match. The combination of high case volume, standardized protocols, and continuous data review has produced the kind of institutional expertise that only comes with scale.
Between 1999 and 2021, Korea's stomach cancer mortality rate dropped from 23.9 deaths per 100,000 to just 5.9 — a reduction to approximately one-fifth of the original rate in just over two decades. This is not a marginal improvement. It's a structural transformation of outcomes through early detection and high-quality treatment.
Source: Cancer Statistics in Korea, Cancer Research and Treatment (e-crt.org), 2024.
| Cancer Type | Korea 5-Year Survival | Global Context |
|---|---|---|
| Stomach Cancer | 69% | Most countries: below 30% |
| Colon Cancer | 72% | Among highest globally (CONCORD-3) |
| Rectal Cancer | 71% | Among highest globally (CONCORD-3) |
All data from CONCORD-3, The Lancet 2018. Individual patient outcomes vary based on stage at diagnosis, treatment protocol, and personal health factors.
We want to be clear about what we're saying and what we're not saying. We're not telling you to get on a plane instead of calling your oncologist. We're saying that the information in this article is real, peer-reviewed, and relevant — and that most American patients making major healthcare decisions have never seen it.
A second opinion from a world-leading center isn't a sign of distrust toward your current care team. It's due diligence. If Korean cancer hospitals are consistently producing survival rates that compare favorably with the world's best for certain cancer types, that is medically material information. You deserve to have it.
The patients who seek care in Korea — many of whom are American, many of whom initially came skeptical — tend to report the same thing afterward: the level of specialization, the volume experience, and the systematic approach felt different. Not foreign. Just precise.
"The data doesn't care about geography. And neither should you."
Population-level survival statistics, including those from CONCORD-3, reflect outcomes across large groups. Individual prognosis depends on cancer stage, subtype, patient health history, age, and many other factors. These statistics are provided for informational purposes to illustrate the quality of Korea's oncology infrastructure — not as a prediction of any individual patient's outcome. Decisions about cancer care should be made in consultation with qualified, licensed oncologists.
All data in this article is sourced from CONCORD-3 (The Lancet, 2018), the Korean National Cancer Screening Program, and Cancer Statistics in Korea (Cancer Research and Treatment journal). This content is for informational purposes only and does not constitute medical advice.
For specific cancers and specific comparison methods, yes. CONCORD-3 — the largest standardized international cancer survival study — found Korea's 5-year stomach cancer survival rate (68.9%) and colon cancer survival rate (72%) among the highest in the world. (Source: Allemani C et al., The Lancet, 2018)
Different registries measure different patient cohorts over different time periods (e.g. Korea Central Cancer Registry 2019–2023 vs. US SEER 2015–2021), so raw comparisons can be misleading. CONCORD-3 is the most methodologically consistent cross-country comparison available.
Stomach and colon cancer are the clearest examples, attributed in part to Korea's nationwide organized cancer screening program and high-volume surgical expertise.
We don't take a commission on patients. We start from the procedure, find the specialist with the best record in it, and connect you to that hospital directly. If we don't think travelling to Korea is right for your case, we'll say so.
Submit an Inquiry info@koremedconsulting.comThe statistics and medical information on this page are drawn from peer-reviewed research and recognised institutions, including the Korea Central Cancer Registry, the American Cancer Society, the Korea Health Industry Development Institute and the OECD. This content is informational only. It is not medical advice, a diagnosis, or a treatment recommendation. Outcomes vary by individual. KoreMed Consulting Group, Inc. is a marketing and consulting agency, not a licensed medical provider. For medical decisions, consult a licensed healthcare professional.